Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RPRX – Royalty Pharma plc

Royalty Pharma plc
RPRX
$44.80
Name : Royalty Pharma plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $25,912,731,648.00
EPSttm : 1.78
finviz dynamic chart for RPRX
Royalty Pharma plc
$44.80
1.21%
$0.535

Float Short %

6.81

Margin Of Safety %

17

Put/Call OI Ratio

0.48

EPS Next Q Diff

-0.02

EPS Last/This Y

2.72

EPS This/Next Y

0.44

Price

44.81

Target Price

51.43

Analyst Recom

1.42

Performance Q

14.99

Relative Volume

1.43

Beta

0.41

Ticker: RPRX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-14RPRX40.210.460.0610043
2026-01-15RPRX39.720.460.1310081
2026-01-16RPRX39.540.460.0610096
2026-01-20RPRX39.040.700.197120
2026-01-21RPRX39.720.690.467219
2026-01-22RPRX40.10.666.017754
2026-01-23RPRX40.40.740.148780
2026-01-26RPRX40.470.680.029399
2026-01-27RPRX40.720.680.019471
2026-01-28RPRX40.410.6758.139531
2026-01-29RPRX40.850.706.289744
2026-01-30RPRX41.670.831.7010369
2026-02-02RPRX42.350.780.0110217
2026-02-03RPRX42.960.780.0010246
2026-02-05RPRX43.850.610.0111785
2026-02-09RPRX44.060.520.0513120
2026-02-10RPRX44.230.521.1113147
2026-02-11RPRX44.260.520.0713310
2026-02-12RPRX44.820.480.0014000
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-14RPRX40.2213.9749.24.64
2026-01-15RPRX39.7213.9734.84.64
2026-01-16RPRX39.5513.9747.74.64
2026-01-20RPRX39.0316.5733.34.64
2026-01-21RPRX39.7116.5781.14.64
2026-01-22RPRX40.1216.5771.14.64
2026-01-23RPRX40.4016.5766.74.64
2026-01-26RPRX40.5216.5759.64.64
2026-01-27RPRX40.7116.5764.54.64
2026-01-28RPRX40.4216.5741.54.64
2026-01-29RPRX40.8515.6773.04.64
2026-01-30RPRX41.6715.6787.64.64
2026-02-02RPRX42.3415.6781.14.64
2026-02-03RPRX42.9615.8778.54.64
2026-02-04RPRX43.6915.8782.74.64
2026-02-05RPRX44.1015.8771.04.64
2026-02-06RPRX44.6515.8775.84.64
2026-02-09RPRX44.0615.8732.24.64
2026-02-10RPRX44.2415.8761.84.64
2026-02-11RPRX44.2715.8756.54.64
2026-02-12RPRX44.8115.8776.24.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-14RPRX-0.74-2.208.56
2026-01-15RPRX-0.74-2.208.56
2026-01-16RPRX-0.74-2.208.56
2026-01-20RPRX-0.74-2.258.56
2026-01-21RPRX-0.76-2.258.56
2026-01-22RPRX-0.76-2.258.56
2026-01-23RPRX-0.76-2.258.56
2026-01-26RPRX-0.83-2.278.56
2026-01-27RPRX-0.83-2.278.56
2026-01-28RPRX-0.83-2.278.18
2026-01-29RPRX-0.83-2.278.18
2026-01-30RPRX-0.83-2.278.18
2026-02-02RPRX-0.83-2.398.17
2026-02-03RPRX-0.85-2.398.17
2026-02-04RPRX-1.05-2.398.17
2026-02-05RPRX-1.05-2.398.17
2026-02-06RPRX-1.05-2.398.17
2026-02-09RPRX-1.053.197.08
2026-02-10RPRX-2.433.197.08
2026-02-11RPRX-2.433.196.81
2026-02-12RPRX-2.373.196.81
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.17

Avg. EPS Est. Current Quarter

1.31

Avg. EPS Est. Next Quarter

1.15

Insider Transactions

-2.37

Institutional Transactions

3.19

Beta

0.41

Average Sales Estimate Current Quarter

839

Average Sales Estimate Next Quarter

859

Fair Value

52.46

Quality Score

61

Growth Score

81

Sentiment Score

82

Actual DrawDown %

8.2

Max Drawdown 5-Year %

-45.5

Target Price

51.43

P/E

25.16

Forward P/E

8.55

PEG

1.15

P/S

10.87

P/B

2.97

P/Free Cash Flow

9.97

EPS

1.78

Average EPS Est. Cur. Y​

4.64

EPS Next Y. (Est.)

5.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.41

Relative Volume

1.43

Return on Equity vs Sector %

-15.9

Return on Equity vs Industry %

0.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

776.2
Royalty Pharma plc
Sector: Healthcare
Industry: Biotechnology
Employees: 100
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
stock quote shares RPRX – Royalty Pharma plc Stock Price stock today
news today RPRX – Royalty Pharma plc stock forecast ,stock prediction 2023 2024 2025
marketwatch RPRX – Royalty Pharma plc yahoo finance google finance
stock history RPRX – Royalty Pharma plc invest stock market
stock prices RPRX premarket after hours
ticker RPRX fair value insiders trading